Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_assertion type Assertion NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_head.
- NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_assertion description "[Furthermore, to determine whether we can apply the results observed in AML to other hematologic malignancies, we investigated the relative levels of nm23-H1 and nm23-H2 transcripts in 149 patients with hematologic neoplasms, including 110 with de novo AML, 9 with de novo acute lymphoblastic leukemia, 14 with myelodysplastic syndrome, 16 with chronic myelogenous leukemia (CML), and 5 normal subjects by the reverse transcriptase-polymerase chain reaction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_provenance.
- NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_assertion evidence source_evidence_literature NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_provenance.
- NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_assertion SIO_000772 9490665 NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_provenance.
- NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_assertion wasDerivedFrom befree-2016 NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_provenance.
- NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_assertion wasGeneratedBy ECO_0000203 NP1389958.RAFn53HQZvG8XbGDsAf3D--F8G2SOCT96cD4W1MUmbudY130_provenance.